Decisive rise in the Moderna stock on Wall Street in the wake of the quarterly report released today. The American biotech group reported net income of $ 2.8 billion ($ 6.46 per share) in the second quarter of the year, against a net loss of $ 117 million in the corresponding period of 2020, while revenues increased by 66 times to $ 4.4 billion. The leap in results is due to the sale of the anti-Covid vaccine, explained the same company. A golden deal, that of the vaccine, for Moderna which, in light of this performance, expects to achieve revenues of 20 billion dollars for the whole of 2021.
Not happy with the profits already recorded, Moderna would have revised upwards the price of the anti-Covid vaccine in the context of the last supply contracts signed with the European Union between now and 2023, after the phase three tests showed greater effectiveness compared to to the others. The Financial Times reported this in recent days, underlining how the same practice has also been adopted by Pfizer.
Research by the People’s Vaccine Alliance, released by Oxfam, would have revealed that the cost of Covid vaccines could be at least 5 times lower if pharmaceutical companies did not take advantage of their monopoly. A new analysis from the Alliance shows that Pfizer / BioNTech and Moderna companies are charging governments up to $ 41 billion more than their estimated production cost. Leading mRNA-type vaccines manufactured by Pfizer / BioNTech and Moderna, which were developed with public funding of $ 8.3 billion, suggest that these vaccines could be produced for as little as $ 1.20 per dose.
Meanwhile, the Moderna title celebrates on Wall Street. In a session with a slight increase, the share of the US biotechnology giant marks an increase of about 3%.